Remus Pharmaceuticals FY26: Scale-up continues, margins soften

FY26 consolidated operational revenue was INR 8,536 Mn, EBITDA was INR 567 Mn, and PAT was INR 462 Mn.

Operational revenue grew 37.6% (INR 6,204 Mn to INR 8,536 Mn), EBITDA grew 24.1% (INR 457 Mn to INR 567 Mn), and PAT grew 20.2% (INR 384 Mn to INR 462 Mn).

The presentation states FY26 business distribution was 86% B2B and 14% B2C.

The presentation reports 903 registered products as of 2026 and 850+ dossiers ready-to-file across geographies.

Highlights include in-licensing Rifaximin and Fexofenadine with bioequivalence support for multiple markets, initiating Semaglutide filings, winning tenders in Nicaragua, Saudi Arabia (NUPCO), and North Macedonia, and launching 26 Relius B2C products in Bolivia with 40 more planned.

FY26 net debt to equity is reported at 0.03 on a consolidated basis and approximately 0.00 on a standalone basis.